1. Academic Validation
  2. Specific bile acids inhibit hepatic fatty acid uptake in mice

Specific bile acids inhibit hepatic fatty acid uptake in mice

  • Hepatology. 2012 Oct;56(4):1300-10. doi: 10.1002/hep.25797.
Biao Nie 1 Hyo Min Park Melissa Kazantzis Min Lin Amy Henkin Stephanie Ng Sujin Song Yuli Chen Heather Tran Robin Lai Chris Her Jacquelyn J Maher Barry M Forman Andreas Stahl
Affiliations

Affiliation

  • 1 Department of Nutritional Science and Toxicology, University of California Berkeley, Berkeley, CA 94720-3104, USA.
Abstract

Bile acids are known to play important roles as detergents in the absorption of hydrophobic nutrients and as signaling molecules in the regulation of metabolism. We tested the novel hypothesis that naturally occurring bile acids interfere with protein-mediated hepatic long chain free fatty acid (LCFA) uptake. To this end, stable cell lines expressing fatty acid transporters as well as primary hepatocytes from mouse and human livers were incubated with primary and secondary bile acids to determine their effects on LCFA uptake rates. We identified ursodeoxycholic acid (UDCA) and deoxycholic acid (DCA) as the two most potent inhibitors of the liver-specific fatty acid transport protein 5 (FATP5). Both UDCA and DCA were able to inhibit LCFA uptake by primary hepatocytes in a FATP5-dependent manner. Subsequently, mice were treated with these secondary bile acids in vivo to assess their ability to inhibit diet-induced hepatic triglyceride accumulation. Administration of DCA in vivo via injection or as part of a high-fat diet significantly inhibited hepatic fatty acid uptake and reduced liver triglycerides by more than 50%.

Conclusion: The data demonstrate a novel role for specific bile acids, and the secondary bile acid DCA in particular, in the regulation of hepatic LCFA uptake. The results illuminate a previously unappreciated means by which specific bile acids, such as UDCA and DCA, can impact hepatic triglyceride metabolism and may lead to novel approaches to combat obesity-associated fatty liver disease.

Figures
Products